Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III – IV congestive heart failure

By Freudenberger Ronald S   Schwarz Jr Richard P   Brown Joanne   Moore Alan   Mann Douglas   Givertz Michael M   Colucci Wilson S   Hare Joshua M  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 11, 2004-11 ,pp. : 1509-1516

Informa Healthcare

Access to resources Recommend Favorite

Remodeling as an End-Point in Heart Failure Therapy

By Cohn Jay  

Cardiovascular Drugs and Therapy, Vol. 18, Iss. 1, 2004-01 ,pp. : 7-8

Springer Publishing Company

Access to resources Recommend Favorite

Clinical Pharmacokinetics and Pharmacodynamics of Allopurinol and Oxypurinol

By Day Richard O.  

Clinical Pharmacokinetics, Vol. 46, Iss. 8, 2007-01 ,pp. : 623-644

Adis International

Access to resources Recommend Favorite

Nesiritide: A Promising New Drug for the Treatment of Decompensated Heart Failure

By  

Heart Drug, Vol. 2, Iss. 1, 2002-04 ,pp. : 39-46

Karger

Access to resources Recommend Favorite

Adenosine therapy: a new approach to chronic heart failure

By Kitakaze M.   Hori M.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 11, 2000-11 ,pp. : 2519-2535

Informa Healthcare

Access to resources Recommend Favorite